CG Oncology, Inc. (CGON)
About CG Oncology, Inc.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$161.0M
- Total assets
- $791.6M
- Market cap
- $4.7B
- Operating margin
- -4722.1%
- Net margin
- -3985.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.0M
- Operating expenses
- $194.8M
- Operating income
- -$190.8M
- Income tax
- -$270.0K
- Net income
- -$161.0M
- EPS (basic)
- $-2.08
- EPS (diluted)
- $-2.08
Balance sheet
- Total assets
- $791.6M
- Current assets
- $759.5M
- Total liabilities
- $39.0M
- Current liabilities
- $30.8M
- Shareholders’ equity
- $752.6M
Cash flow
- Operating cash flow
- -$132.3M
- Investing cash flow
- -$245.8M
- Financing cash flow
- $153.6M
- Net cash flow
- -$224.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $4.7B
- EPS (diluted)
- $-2.08
- Shares outstanding
- 68.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 25, 2024
CG Oncology, Inc. (CGON) Stock Price
- Reported a net loss of $161.0M.
- Revenue grew 255% from FY2024 to FY2025.
- Trading 8% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CG Oncology, Inc..
Write a review
News about CG Oncology, Inc.
News & sentiment via Polygon.io
CG Oncology, Inc.: frequently asked questions
Is CG Oncology, Inc. an American company?
CG Oncology, Inc. is a US-based company headquartered in Dallas, Texas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is CG Oncology, Inc. headquartered?
CG Oncology, Inc. is headquartered in Dallas, Texas, United States.
Is CG Oncology, Inc. publicly traded?
Yes — CG Oncology, Inc. is a publicly traded company. Its stock trades under the ticker symbol CGON on the NASDAQ.
What does CG Oncology, Inc. do?
CG Oncology, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
